Colorectal cancer braf mutation

BRAF VE mutations are rare and occur mostly in tumors located in the ascending colon in elderly female patients. Manipularea tisulară Standardizarea prelucrarii tesutului pentru pacientii cu CmCR rămâne inca o provocare.

Timpul scurs din momentul prelevarii probelor de țesut pana la fixare ar trebui să fie redus la minimum, la numai câteva minute dacă este posibil, pentru a evita orice degradare a proteinelor și a acizilor nucleici care ar putea să apară în timpul ischemiei reci. BRAF is instrumental in establishing prognosis: survival is shorter by months in BRAF-mutant patients, and BRAF may be a negative prognostic factor for patients who undergo hepatic or pulmonary metastasectomy.

Moreover, this mutation is used as a negative predictive factor for anti-EGFR therapies. Two new biomarkers have recently been added to the metastatic colorectal cancer panel: HER2 and microsatellite instability.

While HER2 is still being investigated in different prospective studies in order to validate its prognostic role, microsatellite instability already guides clinical decisions in substituted with advanced colorectal cancer her2 cancer.

Colorectal cancer braf mutation There are current evidences that support using above mentioned colorectal cancer her2 biomarkers to better identify the right medicine that is supposed to be used in the right patient.

This approach contributes to a more individualized patient-oriented treatment in daily clinical practice.